Welcome to the HBV Advocate’s DDW Conference
coverage. In an effort to best serve our
readership, we will post all the important and interesting abstracts about HBV
from the conference. While attending the
conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be
marked with the date that they have been updated and posted. The other abstracts posted to the web site
are HBV related abstracts posted to www.ddw.org
that we have not been able to report on or update.
To locate specific abstracts for each topic below,
click on the links.
Please click here to view our fact sheet on
reading and understanding an abstract.
o 585. Elevated levels of circulating
mesenchymal stem cells in patients with chronic hepatitis B and C
S1226. Diagnostic value of biochemical markers for prediction of liver fibrosis
and inflammation in pediatric patients.
S1340. Clinical Predictors for
Recurrence of Esophageal Varices after Obliteration by Endoscopic Band Ligation
S1765. Changes in Serum Alanine
Aminotransferase (ALT) Level Using a Trajectory Model and Risk of
Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB): The
o T1084. Elevated Serum Alanine
Aminotransferase (ALT) Activity Does Not Increase Cardiovascular Disease (CVD) Mortality
in the United States Population
HBV replication can be controlled
through TLR-induced production of IFN-beta by non-parenchymal liver cells
Prognosis following hepatitis B surface antigen seroclearance: a systematic
review of 9 cohort studies and 1398 patients.
o 94. Presence
of Biopsy-Proven Histologic Damage (Necroinflammation And Fibrosis) is Common
Even When ALT is Less Than 2X ULN in Patients With Chronic Hepatitis B (CHB)
Correlation of hepatic fibrosis with
serum ALT and viral levels in patient with chronic hepatitis B
o 590. Age Greater that 40 is a Stronger Predictor of
Advanced Chronic Hepatitis B (HBV) than Current North American HBV Treatment
Algorithms That Demonstrate Low Predictive Value Regardless of HBeAg, Viral
Load, or Alanine Aminotransferase (ALT).
o M1842. Transient elastography in
chronic hepatitis B and C predicts severe fibrosis similarly
o S1758. Causes of Death Associated
With Hepatitis B or Hepatitis C Virus Infections in a Long-Term
Population-Based Cohort Study
o Portal Hypertension
of prophylactic antibiotics in cirrhotic patients presenting with sepsis.
Band Ligation May Not Be Inferior to Endoscopic Injection Sclerotheraphy in
Cardiac Variceal Bleeding, Not Fundal Variceal Bleeding
Factors Of Nonalcoholic Fatty Liver Disease : Results From A Population-Based
and associated factors of nonalcoholic liver fatty disease and metabolic
syndrome: results from a cross-sectional study
Health Utility Assessment Using SF-6D and Health Utility Index (HUI) in Patients
with Chronic Viral Hepatitis and Non-alcoholic Fatty Liver Disaese (NAFLD)
o M1015. Rates and Predictors of
Depression in an Out-patient Hepatology Practice
Comorbid Medical and Psychiatric Illness and Substance Abuse in HCV-Infected
and Uninfected Veterans
o S1227. Prevalence and risk factors
associated with hepatitis B and hepatitis C virus infections among healthy
population in an urban community in Dhaka, Bangladesh
o S1771. Hepatitis B Patient Survey:
Disease Understanding and Compliance in the United States
o S1775. A Survey of Hepatitis B
Patient Demographics, Disease Characteristics and Management Practice in the
o W1044. Digestive Diseases in the
Native American Population of the U.S. Central Plains: Disparities in
Prevalence, Screening, and Treatment
o S1778. Hepatitis B Prophylaxis in
Patients Undergoing Chemotherapy for Lymphoma: A Decision Analysis Model.
HBV & Liver
o S1728. The Prevalence and Significance of Occult Hepatitis B In A Liver
Transplant population with Chronic Hepatitis C.
o S1730. Beneficial effects of
Short-Term Lamivudine Treatment for de novo Hepatitis B Virus Reactivation
After Liver Transplantation.
o S1779. Prevention Of Hepatitis B Reactivation In Hepatitis B Surface Antigen
(Hbsag) Negative Liver Transplant Recipients From Hepatitis B Core Antibody
(Anti-Hbc) Positive Grafts With Lamivudine Monotherapy
Envelope Protein of the Hepatitis C virus (E2) inhibits IL-2 Secretion from T
o S1736. Impact of Extended Criteria Donor Livers on Survival of Patients with Hepatocellular
o S1766. A Risk Function Nomogram for
Predicting HCC in Patients With Chronic Hepatitis B: The R.E.V.E.A.L.-HBV Study
o Antiviral Treatments for Hepatitis B
95. Tenofovir (TDF)
monotherapy is effective in suppressing serum HBV DNA in chronic hepatitis B
(CHB) patients with primary nonresponse to adefovir (ADV) but not those with
Treatment With Lamivudine And Alpha-Interferon In Chronic Hepatitis B: A Pilot
Prophylaxis is Effective in Reducing Reactivation and Reactivation Related
Liver Mortality: A Meta-Analysis
S1768. A Phase III Comparative
Trial of Telbivudine vs Lamivudine in Chinese Patients with Chronic Hepatitis
B: Two-Year Results.
Lamivudine for Prevention of Chemotherapy-induced Hepatitis B Virus
Reactivation: Meta-analysis of Clinical Trials
(ETV) Results in Higher HBV-DNA Reduction vs Adefovir (ADV) In Chronically
Infected HBeAg(+) Antiviral-Naive Adults: 48-Week Results (E.A.R.L.Y. STUDY).
Randomized Trial of Telbivudine vs Adefovir for HBeAg-Positive Chronic
Hepatitis B: Efficacy Through Week 76, Predictors of Response and Effects of
Switching to Telbivudine
Therapy with Adefovir for Virologic Breakthrough in Telbivudine-Treated
Patients from the GLOBE Study
S1777. Telbivudine Globe Trial at
Year Two: Efficacy, Safety, and Predictors of Outcome in Patients with Chronic
Determination in Patients Experiencing Virologic Breakthrough Following
Telbivudine or Lamivudine Therapy in the International GLOBE Trial.
of Pharmacokinetic Drug-Drug Interaction Between Telbivudine and Tenofovir
93. Genotypic Analysis of
Patients with Evaluable HBV DNA After 1 Year of Telbivudine Therapy in the
GLOBE Registration Trial.
Trial Comparison of Genotypic Response Rates with Adefovir, Entecavir or
Telbivudine for Chronic Hepatitis B